
Eli Lilly Stockpiles $1.5B in Experimental Weight-Loss Drug Ahead of FDA Review
Eli Lilly stockpiles $1.5B of experimental weight-loss drug orforglipron ahead of expected April FDA approval decision, signaling management confidence.
LLYNVOFDA approvalpharmaceutical competition